Literature DB >> 15312123

Herpes simplex virus-based vectors.

Robin Lachmann1.   

Abstract

Herpes simplex virus (HSV)-based vectors have primarily been developed for neuronal gene delivery, taking advantage of the virus' natural neurotropism. Two types of vector are available: replication defective viruses, whose cytotoxicity has been abolished by deleting viral gene products, and amplicon vectors, which are plasmids packaged into HSV particles with the aid of a helper virus. In this review I discuss how the cytotoxicity of the wild-type virus has been abolished, the progress which has been made toward defining promoter elements capable of directing long-term transgene expression form the latent viral genome and some of the potential clinical uses of these versatile vectors.

Entities:  

Mesh:

Year:  2004        PMID: 15312123      PMCID: PMC2517519          DOI: 10.1111/j.0959-9673.2004.00383.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  129 in total

1.  Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency.

Authors:  Guang-Yun Cai; Lewis I Pizer; Myron J Levin
Journal:  J Virol Methods       Date:  2002-06       Impact factor: 2.014

2.  Gene transfer of HSP72 protects cornu ammonis 1 region of the hippocampus neurons from global ischemia: influence of Bcl-2.

Authors:  Stephen Kelly; Zhijian J Zhang; Heng Zhao; Lijun Xu; Rona G Giffard; Robert M Sapolsky; Midori A Yenari; Gary K Steinberg
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

Review 3.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  Herpes vector-mediated expression of proenkephalin reduces bone cancer pain.

Authors:  James R Goss; Cara F Harley; Marina Mata; Mark E O'Malley; William F Goins; XiaoPing Hu; Joseph C Glorioso; David J Fink
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

Review 5.  Virally mediated delivery of enkephalin and other neuropeptide transgenes in experimental pain models.

Authors:  Steven P Wilson; David C Yeomans
Journal:  Ann N Y Acad Sci       Date:  2002-10       Impact factor: 5.691

6.  A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.

Authors:  J G Jacobson; D A Leib; D J Goldstein; C L Bogard; P A Schaffer; S K Weller; D M Coen
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

7.  Intact microtubules support adenovirus and herpes simplex virus infections.

Authors:  Hélène Mabit; Michel Y Nakano; Ute Prank; Bianca Saam; Katinka Döhner; Beate Sodeik; Urs F Greber
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea.

Authors:  William J Bowers; Xiaowei Chen; Huang Guo; D Robert Frisina; Howard J Federoff; Robert D Frisina
Journal:  Mol Ther       Date:  2002-07       Impact factor: 11.454

Review 9.  Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review.

Authors:  Jennifer S Smith; N Jamie Robinson
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

10.  Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse.

Authors:  James R Goss; William F Goins; David Lacomis; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

View more
  17 in total

1.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

2.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

Review 3.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

4.  Viral Vector Biosafety in Laboratory Animal Research.

Authors:  Dalis E Collins; Jon D Reuter; Howard G Rush; Jason S Villano
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

5.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

Review 6.  Recognition of virus infection and innate host responses to viral gene therapy vectors.

Authors:  Dmitry M Shayakhmetov; Nelson C Di Paolo; Karen L Mossman
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

Review 7.  Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges.

Authors:  Sumit Ghosh; Alex M Brown; Chris Jenkins; Katie Campbell
Journal:  Appl Biosaf       Date:  2020-03-01

Review 8.  Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Authors:  Ekati Drakopoulou; Nicholas P Anagnou; Kalliopi I Pappa
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 9.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

10.  Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.

Authors:  Anna Israyelyan; Vladimir N Chouljenko; Abolghasem Baghian; Andrew T David; Michael T Kearney; Konstantin G Kousoulas
Journal:  Virol J       Date:  2008-06-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.